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ABSTRACT
INTRANASAL DELIVERY OF INSULIN BY NANOEMULSION SYSTEM
Darshana Shah
The main objective of this research was to develop an o/w nanoemulsion dosage form
of insulin for intranasal delivery where insulin is loaded into the oil phase of the
nanoemulsion for enhanced absorption. When loaded into the lipid droplets (oil phase),
insulin can be protected from enzymatic degradation, can permeate through the mucus
gel barrier in a comparatively efficient manner and can be absorbed through transcellular
permeation along with paracellular route.
To incorporate lipophilicity to insulin molecule, several complexes of insulin with
various amphiphiles were developed to load it into the oil phase. The cytotoxicity of
these amphiphiles and the developed nanoemulsions was tested on the human nasal
epithelial cells in vitro. An optimized formulation with high loading of insulin and low in
vitro cytotoxicity was developed and characterized.
To predict the absorption of insulin through nasal membrane in vivo by the
nanoemulsion system, the insulin-loaded nanoemulsion along with controls was tested for
the transport across human nasal epithelial cell monolayer in vitro. The nanoemulsion
significantly (p < 0.01) enhanced the permeation of insulin by three times as compared to
the insulin solution.
The in vivo absorption of insulin after intranasal delivery of the insulin-loaded
nanoemulsion was evaluated in anesthetized rats. The results show that the maximum

plasma concentration (Cmax) and the bioavailability (relative to the subcutaneous
delivery) of the insulin-loaded nanoemulsion was 255.9 µU/ml and 68 %, respectively,
while the intranasal delivery of the insulin solution resulted only 5.8 µU/ml of Cmax and
5% of relative bioavailability. Intranasal delivery of 3.6 IU/kg insulin in nanoemulsion
decreased the plasma glucose level remarkably, achieving a maximum reduction of 70%,
and the glucose reduction activity lasted for the whole experimental period of 4 h.
These results demonstrate that the nanoemulsion significantly enhanced insulin
absorption through intranasal delivery, indicating that the developed nanoemulsion
system offers a promising approach for intranasal delivery of insulin.
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CHAPTER 1. INTRODUCTION

Introduction
Peptide and protein drugs are increasingly becoming a very important class of
therapeutic agents. While the peptide and protein therapeutic market has developed
significantly in the past decades, delivery challenge has limited the use of these drugs
(Bruno et al., 2013). The route of administration has a significant impact on the
therapeutic outcome of the drug. The needle and the syringe are a well-established choice
of protein and peptide drug delivery. Parenteral route offers the best absorption but has its
own disadvantages including lack of patient compliance, safety considerations and high
medication cost (Illum, 1991; Muheem et al., 2014). Thus, the noninvasive routes such as
oral, pulmonary, transdermal, buccal and nasal routes have been investigated for protein
and peptide drug delivery.
Oral route is the most popular for systemic absorption of various systemically acting
drugs as it involves ease of administration, large surface area for absorption, patient
acceptability and cost savings to the health care industries. However, most of the peptide
and protein drugs are poorly absorbed when administered orally due to degradation in
gastrointestinal (GI) tract, inefficient transport across the epithelial layer and hepatic first
pass metabolism (Muheem et al., 2014).
Therefore, other non-invasive routes have been extensively explored for protein and
peptide drug delivery. Owing to the physiological characteristics of the respiratory
system, the pulmonary route has received special attention for protein and peptide drug
delivery as it offers a large surface area for drug absorption, rapid drug absorption and
1

avoidance of hepatic first-pass metabolism (Jitendra et al., 2011). Several peptides and
proteins have shown enhanced absorption through pulmonary administration. But
delivery through this route has some limitations such as insufficient deposition of the
drug in deep lungs, local tissue irritation and possibly reduced bioavailability (Klingler et
al., 2009).
The buccal mucosa represents an important site for controlled delivery of protein and
peptide drug with some advantages such as avoidance of hepatic first-pass metabolism,
acidity and protease activity encountered in GI tract (Sudhakar et al., 2006). However,
limited studies have been done for protein drug delivery via buccal mucosa as it has
relatively low permeability and smaller surface area, and the continuous secretion of
saliva leads to subsequent dilution of drug, and swallowing of saliva can potentially lead
to the loss of dissolved or suspended drug (Reddy et al., 2011).
Transdermal delivery of protein and peptide drugs offers an appealing alternative to
other delivery routes as skin is the most accessible organ of the body with a large surface
area and provides a better patient compliance. However, the outermost barrier of skin,
stratum corneum which is made up of dead keratinocytes, acts as a significant rate
limiting barrier. Also the long term adherence of transdermal patches causes patient
discomfort (Kalluri and Banga, 2011).
Recent years have shown that the nasal route can be explored for the systemic
delivery of protein and peptide drugs. Intranasal delivery of protein and peptide drugs
presents myriad benefits such as ease of administration, noninvasive needle-free
administration, rapid onset of action, and the avoidance of gastrointestinal and hepatic
first-pass effects (Ko et al., 1998). Nasal mucosa has a high degree of vascularization and
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high permeability to small molecules, which enables systemic administration of
biopharmaceuticals via this route (Yuba and Kono, 2014).
Conventionally, the nasal route has been used for treatment of local diseases such as
nasal allergy, nasal congestion and nasal infection. In recent years the nasal route has
been explored for the systemic delivery of drugs such as small molecular and high
molecular weight polar drugs, peptides and proteins that are not easily administered via
other routes than injection, or where a rapid onset of action is required (Ozsoy et al.,
2009).

Nasal Cavity
The human nasal passage is about 12 cm long and runs from the nostrils to the
nasopharynx (Fig. 1) (Gad and Wiley InterScience (Online service), 2008) . The nasal
cavity is divided into two halves by the nasal septum and extends posteriorly to the
nasopharynx, while the most anterior part of the nasal cavity, the nasal vestibule, opens to
the face through the nostril. The atrium is an intermediate region between the vestibule
and the respiratory region. The respiratory region, the nasal conchae or turbinates, which
occupies the major part of the nasal cavity, possesses lateral walls dividing it into three
sections: the superior, middle and inferior nasal turbinates. The presence of these
turbinates creates a turbulent airflow through the nasal passages which ensures a better
contact between the inhaled air and the mucosal surface (Illum, 2003). Maximum drug
absorption in nasal cavity takes place at the respiratory region as it has vast surface area
and is rich in vascularity.
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The nasal respiratory mucosa is covered with mucus. The mucus is about 5 µm thick
and has a viscous gel on the upper part and an aqueous solution layer on the lower part
(Arora et al., 2002). Nasal epithelium is covered with new mucus layer approximately
every 15 min (Lansley, 1993). The mucosal secretion contains 95% water, 2% mucin,
1% salt, 1% albumin, immunoglobulin, lysozyme, lactoferin and other proteins and 1%
lipids. Nasal mucus also contains IgA, IgE and IgG (Lansley, 1993; Ugwoke et al., 2001).

Fig. 1. Nasal Cavity: nasal vestibule (A), atrium (B), respiratory area and inferior
turbinate (C1), middle turbinate (C2) and superior turbinate (C3), olfactory region (D),
and nasopharynx (E) (Gad, 2008).

Compared to other biological membranes the nasal mucosa is relatively porous, and
thin, and has a rapid blood flow and a vast absorption area (150 cm2) with microvilli on
the epithelial cells (Ugwoke et al., 2001).

4

Limitations of Intranasal Delivery
Even though the nasal epithelium is suitable for systemic delivery of a variety of
drugs, the drug absorption is limited due to following main factors (Schmidt et al., 1998):
•

Limited application volume (25 – 250 µl)

•

Difficulty in permeability of high molecular weight (>1000 Da) drugs through
nasal epithelium

•

Mucociliary clearance

•

The enzymatic barrier of the epithelium
The volume that can be delivered to the nasal cavity is restricted to 25 – 250 µL.

Therefore different approaches have been explored to use this volume effectively
including the use of solubilizers and gelling agents (Arora et al., 2002). The use of
solubilizer increases the aqueous solubility of insoluble compounds and can even
promote the nasal absorption of the drug. Gelling agent decreases the drainage and results
in increased retention of drug in nasal cavity.
The molecular size of the drug influences intranasal absorption. The rate of
permeation is highly sensitive to molecular size for compounds with molecular weight
(MW) ≥ 300 Daltons (Corbo et al., 1990). A large number of therapeutic agents, peptides
and proteins in particular have shown that for compounds > 1 kDa, bioavailability can be
directly predicted by MW. In general, the bioavailability of these large molecules ranges
from 0.5% to 5% (Donovan and Huang, 1998).
Another factor for low absorption is the rapid clearance of the administered
formulation from the nasal cavity due to mucociliary clearance (MCC) mechanism. It is a
normal defense mechanism of the nasal cavity that clears mucus as well as substances
5

adhering to the nasal mucosa (bacteria, allergens etc.) and drains them into the
nasopharynx for eventual discharge into the gastrointestinal tract. Whenever a substance
is nasally administered, it is cleared from the nasal cavity in about 21 min by MCC
(Marttin et al., 1998). Reduced mucociliary clearance increases the contact time of a drug
and the mucus membrane and subsequently enhances the drug permeation (Lansley,
1993).
Nasally administered drugs circumvent gastrointestinal and hepatic first-pass effects.
However, they might be metabolized to some degree in the lumen of the nasal cavity or
during passage across the nasal epithelial barrier because of the presence of metabolic
enzymes in nasal tissues. Nasal epithelium and nasal secretions possess a wide range of
enzymes. Nasal epithelium contains carboxyl esterases, aldehyde dehydrogenases,
epoxide hydrolases, and glutathione S-transferases. They are responsible for the
degradation of drugs in nasal mucosa (Yuba and Kono, 2014). The nasal mucosa also
includes oxidative phase I and conjugative phase II enzymes. The phase I enzymes
include aldehyde dehydrogenase, carboxyl esterase, and carbonic anhydrases; Phase II
enzymes include glucuronyl, sulfate and glutathione transferases (Gad and Wiley
InterScience (Online service), 2008). Proteolytic enzymes (aminopeptidases and
proteases) present in nasal mucosa are believed to be one of the barriers against the
absorption of protein & peptide drugs such as calcitonin, insulin and desmopressin (Pires
et al., 2009).
Zhou et. al. compared the aminopeptidase activity in nasal, buccal, dermal and
intestinal tissue homogenates. The study reported that the nasal homogenates showed half
of the intestinal aminopeptidase activity (Zhou and Po, 1990). Although enzymatic
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activity is present in the nasal cavity, this activity is generally lower than the enzymatic
activity of the gastrointestinal tract, making this route an attractive alternative to the oral
delivery of enzymatically labile drugs such as therapeutic peptides and proteins (Hillery
et al., 2002).
In spite of these hurdles, the nasal route is still considered to be superior to the oral
route for protein and peptide delivery as it avoids harsh GI environment, presents
relatively less enzymatic degradation and has highly vascularized epithelial tissue with
similar permeability as the small intestine (Arora et al., 2002).
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CHAPTER 2. LITERATURE REVIEW, HYPOTHESIS AND
OBJECTIVES

Studies have shown that through nasal delivery, the bioavailability of the peptide
and proteins is inversely proportional with their molecular weight and number of amino
acids. In other words, the absorption of drugs via nasal mucosa decreases as the
molecular weight increases. Absorption is particularly low for high molecular weight
drugs applied as simple aqueous solutions. So, several strategies have been employed to
improve the nasal bioavailability of proteins and peptides. Most popular approaches can
be summarized as follows:
•

Modification of the chemical structure of the drug
Modification of the chemical structure of the peptides and proteins may increase
the metabolic stability and/ or membrane permeability (Nash et al., 2002). The
nasal absorption of L-tyrosine and the effect of structural modification on its
absorption have been studied by an in situ experimental technique (Huang et al.,
1985). It was assessed that chemically modified carboxylic acid esters were
absorbed 4-10 times faster than L- tyrosine.

•

Enzyme inhibitors
Proteins and peptide drugs can be applied with enzyme inhibitors to protect them
from the enzyme activity present in nasal mucosa (Behl et al., 1998). Inhibitors
with a trypsin-inhibiting activity have been proved to be useful in enhancing the
nasal absorption of salmon calcitonin (Morimoto et al., 1995).

•

Absorption enhancers
8

Inclusion of absorption enhancers (such as bile salts and surfactant, fusidic acid
derivatives, phosphatidylcholines and cyclodextrins) may enhance the passage of
drugs with polar structure through nasal mucosa (Ozsoy et al., 2000). Calcitonin,
a polypeptide of 3.4 kDa, showed enhanced nasal absorption in rats when it was
delivered with 5% methylated β-cyclodextrin derivative as an absorption enhancer
(Adjei et al., 1992).
•

Novel formulations
Novel formulations including drug carrier system such as liposomes, gels, lipid
emulsions, niosomes, nano and microparticle have been studied to enhance the
nasal absorption (Brooking et al., 2001; Gungor et al., 2010; Kumar et al., 2009;
Mitra et al., 2000). Nasal administration of insulin-loaded polyacrylic acid
microparticles suspended in 1% (w/v) polyacrylic acid gel resulted in a noticeable
and sustained hypoglycemic effect for seven hours in normal rabbits (Dondeti,
1991).

2.1.

Human Insulin
Insulin is a 51 amino acid peptide that was discovered in 1921 by Frederick

Banting and Best, together with MacLeod and Collip (Fig. 2). It is secreted by pancreatic
β cells and has the ability to control glucose levels in blood by facilitating glucose uptake
into the cells of the organism. The most common therapy for diabetes mellitus is the
injection of insulin. But it is a painful and inconvenient approach, resulting in poor
patient compliance (Pillai and Panchagnula, 2001). In recent decades, oral delivery of
insulin has been widely investigated because it can improve patient compliance (Trehan
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and Ali, 1998). However, there are various obstacles for oral administration of insulin,
mainly its poor absorption properties, poor absorption from the intestinal lumen and
susceptibility to chemical and physiological degradation (Jintapattanakit et al., 2007).
Nasal delivery of insulin may be a suitable approach as it avoids harsh environment
of GI and hepatic first pass effect. Multiple studies have been done with different
strategies to enhance intranasal absorption of insulin including particulate delivery,
inclusion of absorption enhancers, using enzyme inhibitors and lipid-based formulations.
Proteolytic enzyme inhibitors could prevent the hydrolysis of peptide and protein
drugs in the nasal cavity and thus, improve the stability of drugs at the absorption site.
Aungst and Rogers (Aungst and Rogers, 1988) reported an improvement in intranasal
insulin absorption in rats by co-administration of aprotinin, a serine protease inhibitor.
Efficacy, relative to an intramuscular dose, was improved from 0.4% for the control
insulin solution to 9.6% in the presence of aprotinin. However, proteolytic enzyme
inhibitors themselves cannot facilitate the penetration of drugs across the epithelial
membrane and therefore, are generally unable to considerably improve bioavailability in
the absence of absorption enhancers. Furthermore, the enzyme inhibitors will affect the
normal metabolism of the body, resulting in serious side effects. Therefore, enzyme
inhibitors do not seem to be an effective and safe method of improving the nasal
absorption of insulin.
The use of absorption enhancers or promoters has been the most common approach
to improve the nasal absorption of insulin. Ideally, absorption promoters should be rapidacting, resulting in transient and reversible modulation of the absorptive properties or
physiology of the nasal mucosa, and not be absorbed systemically. They should be
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devoid of any toxic, irritating or allergic activity. So far, many compounds – such as
surfactants (e.g. 0.5% lysophosphatidylcholine (LPC), 0.5% laureth-9, 1.0% sterol
glucoside), bile salts and its derivatives (e.g. 1% sodium deoxycholate, 1% sodium
taurodihydrofusidate), fatty acids and its derivatives, cyclodextrins, cell penetrating
peptides, chelators and cationized polymers – have been investigated as absorption
enhancers for nasal delivery of insulin (Aungst and Rogers, 1988; Illum et al., 1989;
Moses et al., 1983) . These absorption enhancers are effective in improving the nasal
absorption by increasing the nasal fluidity of bilayer membrane and by opening aqueous
pores as a result of calcium ion chelation. However, they tend to cause severe nasal
irritation and damage nasal membrane at the concentrations required to effectively
promote nasal absorption (Davis and Illum, 2003). For example, surfactants such as
laureth-9 damages epithelial membrane by dissolving the membrane lipids or proteins,
resulting in cell erosion, cell to cell separation and loss of the cilia (J.M. Pezzuto H.R.
Manasse, 2013). Haffejee et. al. evaluated the toxicity of LPC on rat nasal epithelium.
Transmission electron microscopy (TEM) results showed that 1% w/v LPC caused severe
epithelial damage and total loss of ciliated cells (Haffejee et al., 2001). The nasal
epithelial layer serves as a defense against infecting organisms, and therefore loss or
damage of this layer can cause severe problems.
The mucoadhesive approach has been developed to improve intranasal drug
absorption because it could prolong the intimate contact time of the formulation on the
nasal mucosa by adhering to the surface of the mucus layer and thereby enhancing the
bioavailability. Microspheres have been suggested to exert several mechanisms for
absorption-enhancement effects on the nasal delivery of peptides and/or proteins.
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Microspheres deposit in the less- or non-ciliated anterior part of the nasal cavity with
slower nasal clearance. The bioadhesive effect of the microspheres decreases the rate of
clearance of the drug from the nasal cavity and thereby enables a longer contact time with
the absorptive epithelium (Edman et al., 1992). The gelled system provides a local high
drug concentration in close contact with the epithelial absorptive surface. Furthermore, it
has been shown in a study employing monolayers of Caco-2 cells that the absorption of
water by the microspheres from the mucus layer can induce reversible and transient
shrinking of the epithelial cells and widening of the tight junctions and, therefore, the
transport of hydrophilic compounds could be increased (Haffejee et al., 2001). Callens et
al. (Callens et al., 2003) demonstrated that the bioavailability of insulin obtained with the
powder formulations containing drum-dried waxy maize starch and Carbopol® 974P
were significantly higher than those containing maltodextrins and Carbopol® 974P
mixtures. The bioavailability of insulin increased as the ratio of Carbopol® 974P
increased. The absolute bioavailability in the powder formulation containing drum-dried
waxy maize starch and 10% Carbopol® 974P was as high as 14.4%. Morimoto et al.
(Matsuyama et al., 2006) reported that the nasal administration of insulin in 0.1% and 1%
(w/v) polyacrylic acid gels showed maximum hypoglycemic effects at 30 min and one
hour after administration, respectively. However, it is generally difficult to achieve a
satisfactory effect for macromolecular drugs by increasing retention time in the nasal
cavity alone because it has to simultaneously overcome the physical barrier of the
epithelium for a drug to permeate into the systemic circulation.
As nanotechnology-based drug delivery systems have become accessible to fill the
pharmaceutical R&D pipeline, nano-sized emulsions (conventionally called
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microemulsions) have been one of the most attractive formulations as potential drug
carriers to enhance the uptake across nasal mucosal membrane (Sintov et al., 2010).
Nanoemulsions are thermodynamically stable systems with the droplet size usually less
than 100 nm. Nanoemulsions have been widely studied to increase the bioavailability of
poorly water-soluble drugs. Poorly water-soluble drugs are easily dissolved in the oil
phase as they are hydrophobic in nature. The mechanisms for the increase in the
bioavailability are due to improvement of drug solubilization, protection against
enzymatic degradation and the increased surface area of droplets (Rao et al., 2008b).
Nanoemulsion formulation has several advantages such as ease of preparation, cost
effective and easy to administer to the patient. Literature review indicates that there were
only two publications on intranasal delivery of insulin by emulsion formulations.
Mitra et. al. (Mitra et al., 2000) reported that insulin absorption through rat’s nasal
mucosa was enhanced by o/w emulsion system, where insulin was loaded in the aqueous
phase. AUC was observed 4 times higher for o/w insulin loaded emulsion than the insulin
buffer solution. The authors had also prepared w/o emulsion where insulin was loaded in
the aqueous phase, and did not observe any increase in absorption. Emulsion formulation
for this study contained soybean oil, tween 80 and span 80. Measured droplet size for o/w
emulsion was around 4 µm whereas w/o showed broader distribution from 1µm to 10
µm.
Sintov et. al. (Sintov et al., 2010) demonstrated that intranasal delivery of o/w
microemulsion system with 20% water content (insulin in the aqueous phase) achieved an
absolute bioavailability of 7.5% in rabbit. Bioavailability was observed negligible when
the water content was increased to 50% for the o/w microemulsion formulation. The
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microemulsion formulation used for this study contained isopropyl palmitate, glyceryl
oleate, labrasol and propylene carbonate. Measured droplet size for both w/o & o/w
ranged between 10-20 nm by TEM.
In the above two studies, insulin was loaded in the aqueous phase of the emulsion
system. First study by Mitra et. al. showed enhanced permeation of insulin by o/w
emulsion. This enhancement might be due to the components of the formulation such as
surfactants which might have opened the tight junctions of the nasal epithelium. An
insulin solution with surfactants probably would show the similar effect, but authors did
not study the effect of insulin solution with surfactants. The other possibility for
enhanced insulin permeation could be slow mucociliary clearance process due to
adherence of the lipid droplets to the nasal epithelial membrane which may be achieved
by use of certain mucoadhesive agents.
In the second study by Sintov et al., again, since insulin was in the external aqueous
phase, the purpose of forming nanoemulsion was defeated. The enhancement by 20%
water content nanoemulsion was probably due to the viscosity effect together with the
surfactant’s effect on the nasal epithelium.
Rao et al. (Rao et al., 2008a) used β-lactamase (BLM) as the model protein drug and
demonstrated that when the drug loaded inside the lipid droplets of o/w nanoemulsion (40
nm), the transportation through MDCK cell monolayer was increased more than 25 times
compared to the solution form while the micelle formulation only increased 3 times. It
was reported that there was significant increase in transport of BLM through MDCK cell
monolayer only when it was loaded inside the inner oil phase of nanoemulsion as
compared to BLM aqueous solution. Also, Koga et al. (Koga et al., 2010) reported that
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following intraduodenal administration in rats, increase serum concentration of calcein
was higher from w/o/w emulsion (300 nm) when calcein was in the inner water phase as
compared to when calcein was in the outer water phase of w/o/w emulsion (300nm).

2.2

Hypothesis

The above studies on nanoemulsions imply that loading protein or peptide into the
oil phase of nanoemulsions may enhance the absorption due to mucus permeating
properties of lipid droplet, protection against enzymatic degradation, reversible opening
of tight junctions and transcytosis. Therefore, we hypothesize that loading insulin into the
oil phase of nanoemulsions may enhance the intranasal absorption of insulin.

2.3

Research Objective

To develop a nanoemulsion system for intranasal delivery of insulin.

The specific objectives are as follows:
I.

To develop and characterize an o/w nanoemulsions where insulin is loaded inside
the oil phase

II.

To evaluate the transport of insulin by such a nanoemulsion through human nasal
epithelial cell monolayer in vitro

III.

To evaluate the in vivo intranasal absorption of insulin such by a nanoemulsion in
rats
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Fig. 2. Human insulin structure.
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CHAPTER 3. FITC LABELING OF INSULIN AND TRANSPORT OF
FITC-INSULIN CONJUGATES THROUGH MDCK CELL
MONOLAYER

Introduction
Fluorescent probes are less expensive, much safer, more stable and much easier to
dispose than radioisotopes, and hence they have gained much attention over the last
several decades (Rogers, 1997). Fluorescein isothiocyanate (FITC), one of such probes, is
widely used for labeling proteins and peptides due to its high detection sensitivity and
low molecular size which has potentially low impact on the protein/peptide’s biological
activity (Ueno and Nagano, 2011).
FITC is an amine reactive fluorescent probe which labels biomolecule by forming a
covalent bond between its isothiocyanate group and the primary and secondary amine
groups of biomolecules (Banks and Paquette, 1995). FITC (MW 389.4) labeling of
human insulin (MW 5807.57) may give mono-, di- and tri- conjugates of insulin since
insulin has three primary amine groups (Jacob et al., 2016). Insulin has been previously
labeled with FITC and characterized for a number of applications such as protein tracing,
protein-protein interaction, assay, analytical detection, microsequencing, drug release
study, permeability and cellular uptake study by fluorescence microscopy (Gök and
Olgaz, 2004; Hentz et al., 1997; Jacob et al., 2016; Jobbágy and Jobbágy, 1973; P. Li et
al., 2016). However, these reported labeling methods are tedious, which takes more than
12 h to produce different conjugates of FITC-Insulin. The reported protocols for labeling
are not robust. FITC labeled insulin is also commercially available and has been used by
researchers, but is comparatively expensive (P. Li et al., 2016; Ma and Lim, 2003).
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Hence, there is still a need to develop an easy, quick and reliable labeling method to
prepare different conjugates of FITC labeled insulin. Therefore, one of the aims of the
present work is to study the reaction conditions to produce different conjugates of FITCInsulin and to develop relatively simple and robust method.
The conjugation at different sites affects the biological activity of insulin. The
biological activity of the FITC-Insulin conjugates has been reported to differ from that of
the native insulin. Hentz et al. studied the biological activity of each conjugate and found
that mono labeled FITC-Insulin (tagged at B1 position) had the same biological activity
as the native insulin whereas A1 conjugated FITC-Insulin showed 10% decrease in the
biological activity and di & tri conjugated FITC-Insulin showed 100% decrease in
biological activity as compared to the native insulin (Hentz et al., 1997). The different
conjugates may also affect the permeability of insulin due to the difference in molecular
weight, hydrophilicity and lipophilicity. To our knowledge, no reports till date have been
published regarding the effect of different conjugation on the permeability of FITCInsulin across a biological membrane. Therefore, the second aim of the present study is to
investigate the impact of different FITC conjugates on the hydrophilicity and lipophilicity
of insulin and its permeability through a cell monolayer.

Materials
Human insulin and FITC-Insulin (Human) were purchased from Sigma-Aldrich,
Co. (St. Louis, MO, USA). Fluorescein Isothiocyanate, Isomer I, 95% (FITC) was
purchased from Alfa Aesar (Tewksbury, MA, USA). PD-10 SephadexTM G-25 M
Columns were purchased from GE Healthcare (Buckinghamshire, UK). Dulbecco’s
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Modified Eagle’s Medium (DMEM), Hyclon TM Hank’s 1X Balanced Salt Solution
(HBSS), Penicillin-Streptomycin Solution and Trypsin-EDTA Solution were purchased
from Fisher Scientific (Middletown, VA, USA). Transwell® inserts were purchased from
VWR International (Allison Park, PA, USA). Human Insulin ELISA Kit was purchased
from Crystal Chem (Elk Grove Village, IL, USA). MDCK cell line was purchased from
ATCC® (Rockville, MD, USA).

Methods
FITC Labeling of Human Insulin
FITC solution in DMSO (5 mg/ml) was added dropwise with gentle stirring to
human insulin solution (15 mg/ml) in 0.1 M bicarbonate buffer (pH 9.5) with the molar
ratio of FITC:Insulin varying from 0.25:1 to 5:1. The reaction mixture was protected
from light and kept at room temperature for 0.5-4 h with continuous slow stirring. Then
the reaction mixture was incubated at room temperature for 30 min without stirring. The
reaction mixture was then passed through a PD-10 SephadexTM G25 column to separate
the unbound FITC from insulin and FITC-Insulin conjugates. Phosphate buffer (pH 7.4)
was used to elute the mixture from the column and the eluent was collected in 32
fractions (fraction volume – 0.5 ml). Each fraction was analyzed by HPLC to quantify
and determine the labeling efficiency. The fractions containing the conjugates were
combined together and lyophilized overnight. The lyophilized FITC-labeled insulin
powder was stored at -20o C for further use.
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HPLC Assay
The HPLC assay of insulin and FITC-Insulin was carried out on an Agilent 1260
system equipped with an Agilent 1260 series UV detector and an Agilent 1220 series
fluorescence detector. The analysis conditions were as follows: Column: C18, 5 µm, 4.6
X 150 mm; Flow rate: 1 ml/min; Injection volume: 20 µl; UV detector wavelength: 220
nm; Fluorescence detector wavelengths: Excitation – 495 nm, Emission – 525 nm;
Mobile phase A: Deionized water with 0.1% trifluoracetic acid (TFA); Mobile phase B:
90% Acetonitrile and 10% deionized water with 0.1 % TFA; Run time: 45 min. Gradient
elution was used according to Table 1.
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Table 1. HPLC gradient elution schedule.

Time (min)

Mobile phase composition

0

85% A + 15% B

15

65% A + 35% B

25

35% A + 65% B

32

35% A + 65% B

33

100% B

43

100% B

44

85% A + 15 % B

A: Deionized water with 0.1% TFA
B: 90% Acetonitrile and 10% deionized water with 0.1%TFA
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Lipophilicity and Hydrophilicity Assay of the Conjugates
The lipophilicity and hydrophilicity of the conjugates were determined by the
analysis of the partition coefficient (P). The method described by Griesser et al. (Griesser
et al., 2017) was adopted with slight modification. In brief, buffer (pH 7.4) containing 1
mg/ml of either FITC-Insulin conjugates or unlabeled insulin was added to 1-octanol
(1:1) and incubated for 8 h at 37o C while shaken at 300 rpm. The samples were
centrifuged for 10 min at 9,000 rcf. Aliquots (100 µl) were withdrawn from both the
phases and analyzed for absorbance and fluorescence by HPLC. Partition coefficient (P)
was calculated as the ratio of the insulin concentration in the octanol phase vs in the
aqueous phase.
Transport of FITC-labeled Insulin through MDCK Cell
Monolayer
The MDCK cells were grown in 75-cm2 Corning flasks in DMEM supplemented with
10% (v/v) fetal bovine serum and 1% penicillin-streptomycin solution at 37o C with 5%
CO2 and 95% air with high humidity. The cells were harvested by trypsin-EDTA solution
once they reached 80% to 90% confluency, and then seeded on 24 Transwell® inserts (1µm pore size, 0.33-cm2 growth area) at 6.3 X 104 cells/cm2 with 0.3 ml growth media on
the apical side. One ml growth media was added on the basolateral side. The growth
media was changed every other day and TEER value was measured. The transport was
run on Day 7 once the monolayer had been formed and the TEER value had reached
above 300 Ω·cm2. The monolayer was washed twice with HBSS and incubated in HBSS
for 30 min. Then the transport media on the apical side was replaced by 0.3 ml of
unlabeled insulin or FITC-Insulin (2 mg/ml in HBSS). Samples of 200 µl each were
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withdrawn from the basolateral side at the predetermined time points until 3 hr. After
each withdrawal, same volume of fresh HBSS was added to the basolateral side. The
samples containing FITC-Insulin were analyzed for fluorescence by a plate reader
(Excitation filter: Blue 475 nm, Emission filter: 500-550 nm) and unlabeled insulin was
analyzed by ELISA.

Results & Discussion
FITC Labeling of Human Insulin
Human insulin has 51 amino acids divided into two chains: Chain A containing 21
amino acids and Chain B containing 30 amino acid (Fig. 3). There are three primary
amine groups in an insulin molecule. Bromer et al. reported that FITC could bind to the
three primary amine sites and form mono-, di- and tri-conjugated FITC-Insulin. The order
of reactivity of the three primary amines was found to be B1 (Phe) > A1 (Gly) > B29
(Lys) (Bromer et al., 1967).
In the present study, the labeling reaction was conducted at different molar ratios of
FITC to Insulin and different reaction time to investigate the impact of these two factors
on the products (mono-, di- and tri-conjugated FITC labeled insulin). The reaction
mixture after the gel filtration was analyzed by a HPLC connected with an absorbance
detector (VWD) and a fluorescence detector (FLD). FITC-labeled insulin gave peaks in
both the absorbance and fluorescence chromatograms at around the same retention time,
whereas the unlabeled insulin showed a peak only in the absorbance chromatogram but
not in the fluorescence chromatogram. Among the 32 fractions from the gel filtration,
Fractions 4-9 had the labeled insulin, showing peaks in both chromatograms, and they
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were combined. Fig. 4 and Fig. 5 represents the chromatograms of the combined
Fractions 4-9 from each reaction as compared to the unreacted insulin (Fig. 5I), the
unreacted FITC (Fig. 5H) and the commercial FITC-Insulin (Fig. 4E). Based on the
previous reports (Hentz et al., 1997; Jacob et al., 2016), the peaks in the absorbance
chromatograms were identified as follows: Peak 1 – unlabeled insulin; Peak 2 – monoconjugated FITC-Insulin at B1; Peak 3 – mono-conjugated FITC-Insulin at A1; Peak 4 –
di-conjugated FITC-Insulin at B1 and A1; Peak 5 – tri-conjugated FITC-Insulin at B1,
A1 and B29.
When reaction was carried out for 150 min, different molar ratios of FITC:Insulin
produced different conjugates which showed peaks in both detectors as follows (Fig. 4):
A) 1:1 molar ratio had unlabeled insulin and it produced mono- and di-conjugates with
little quantity of tri-conjugates. B) 2:1 molar ratio produced di- and tri-conjugates where
di-conjugate was determined to be in higher amount than tri-conjugate. C) 3:1 molar ratio
showed both di-and tri-conjugates where tri-conjugate was determined to be in higher
amount than di-conjugate. D & F) Molar ratio 4:1 and 5:1 produced tri-conjugate with
very little quantity of di-conjugates.
Molar ratio 0.25:1 with 90 min of reaction time gave mono-conjugated FITC-Insulin
along with unlabeled insulin (Fig. 5G). The chromatograms of the products from molar
ratio 3:1 FITC-Insulin were similar as that of the commercial FITC-Insulin (Fig. 4C &
4E). Increasing the reaction time for 4:1 to 240 min did not give pure tri-conjugated
FITC-Insulin. The products still had small quantity of di-conjugates. Unbound FITC gave
peaks at 11 min and 22 min (Fig. 5H) which further confirmed the absence of unbound
FITC in the labeled insulin fractions.
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Fig. 3 Primary structure of human insulin with grey colored circles indicating primary
amine sites for FITC labeling.
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Fig. 4. Chromatograms of the FITC labeled insulin. A), B), C), D) and F): with 150 min
reaction time and with FITC:Insulin molar ratio of 1:1, 2:1, 3:1, 4:1 and 5:1 respectively,
E) Commercial FITC-Insulin.
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Fig. 5. Chromatograms: G) FITC labeled insulin (0.25:1 molar ratio, 90 min reaction
time), H) Free FITC, I) Unlabeled Insulin.
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Lipophilicity and Hydrophilicity of FITC-Insulin
In order to evaluate the lipophilicity and hydrophilicity of the FITC-labeled insulin,
the partition coefficient (P) of the unlabeled insulin, mono- and tri-labeled insulin in the
octanol/water system was determined. P value of the unlabeled insulin, mono-conjugate
and tri-conjugate was determined to be 0.07 ± 0.04, 0.08 ± 0.04 and 0.12 ± 0.02
respectively.

Transport of FITC-labeled Insulin through MDCK Cell
Monolayer
MDCK cells have been used as a model cellular barrier for predicting the intestinal
epithelial drug transport for many years (Rao et al., 2008a), and take comparatively short
time to grow and form tight junction when growing on semi-permeable membranes.
Therefore, MDCK cell monolayer was chosen for this study to determine the effect of
FITC labeling of insulin on its transport. The mono-conjugated FITC-Insulin, triconjugated FITC-Insulin along with the unlabeled insulin were chosen for the transport
study. The results are presented in Fig. 6 and Fig. 7.
The unlabeled insulin and mono-conjugated FITC-Insulin showed significantly higher
(p < 0.05) transport than tri-conjugated FITC-Insulin (Fig. 7). Even though, the partition
coefficient value of tri-conjugated FITC-Insulin is higher than mono-conjugate and
unlabeled insulin, it showed decreased transport due to the increase in molecular weight
(Fig. 6). Molecular weight of tri-conjugate is higher than the mono-conjugate due to the
attachment of three FITC molecule to one insulin molecule as compared to monoconjugate where one FITC molecule is attached to one insulin molecule.
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FITC is much more hydrophobic (log P = 5.25) than insulin (Schroeder and
Macguidwin, 2010). Mono-conjugated insulin showed slightly higher but not
significantly different transport than the unlabeled insulin. Slightly increased permeation
could be due to the lipophilicity induced by FITC molecule. Increase in molecular weight
of insulin conjugate could be the reason for decreased permeability of tri-conjugated
FITC-Insulin through MDCK cell monolayer.
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Fig. 6. Permeability coefficient (Papp), molecular weight and partition coefficient (p)
value of unlabeled insulin, mono- and tri-conjugates (mean ± S.D., n ≥ 3).
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Fig. 7. Transport of mono- and tri-conjugated FITC-Insulin and unlabeled insulin through
MDCK monolayer, (mean  S.D., n=6).
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Conclusion
A quick, reliable and relatively simple method was developed to synthesize the
different conjugates of FITC-Insulin. Extent of conjugation of FITC to insulin did affect
the permeability of insulin across cell monolayer.
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CHAPTER 4: FORMULATION DEVELOPMENT AND IN-VITRO
STUDY

4.1.

Introduction
Nasal drug delivery has been investigated as an alternative administration route for

oral and injection routes. Small molecular compounds and biomacromolecules have been
tested for delivery via the nasal route in various formulations. Many formulation
approaches have been used to enhance the absorption of macromolecules. The
mechanism of absorption enhancement may involve many factors such as local alteration
in the membrane structure and modification of its permeability, bioadhesion of the
peptide drug to the mucosal surface and lowering of the mucociliary clearance and
opening of cellular tight junctions (Marttin et al., 1998, 1995; Shao et al., 1993;
Shinichiro et al., 1981). Medium chain fatty acids have been found to enhance the
absorption of macromolecules by reversibly opening the tight junctions (P. Li et al.,
2016).
The preconcentrate of self-emulsified nanoemulsions are isotropic mixtures of oil(s),
surfactant(s) and with or without a co-surfactant(s). When some of these components are
mixed in specific ratios, they form oil-in-water nanoemulsion upon addition of buffer or
water with droplet size of less than 150 nm. Nanoemulsion systems have been proved to
be effective in enhancing the oral bioavailability of many large molecules by providing
large surface area for absorption, enhancing permeation due to reversible opening of tight
junctions and protecting drugs against enzymatic degradation (AboulFotouh et al., 2018;
Hintzen et al., 2014). When loaded into the lipid droplets, the peptide drug can be
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protected from enzymatic degradation, can permeate through the mucus gel barrier in a
comparatively efficient manner and can be absorbed through transcellular permeation as
well as paracellular route (Hintzen et al., 2014; Karamanidou et al., 2015; Rao et al.,
2008a).
However, it is difficult to load peptide/protein drugs into lipid due to their hydrophilic
nature. This challenge can be overcome by incorporation of hydrophobicity to peptide
and protein drugs. Two strategies have been reported in literature to make hydrophilic
peptides and proteins more lipophilic and thereby to increase their ability to be
incorporated in lipid-based drug delivery systems (Cui et al., 2006; Rao and Shao, 2008;
Zhang et al., 2012).
Hydrophobic ion-pairing (HIP) strategy is based on ionic interaction between charged
proteins and oppositely charged surfactants. This technique has proved to increase the
drug encapsulation efficiency, enhance the permeability and drug transport across
membranes and improve oral bioavailability (Anderberg et al., 1993; Aungst and
Hussain, 1992; Lee et al., 1991). HIP complexes are reversible in nature and charged
protein can easily dissociate in presence of excess of oppositely charged ions (Gaudana et
al., 2011). Sodium deoxycholate (SDC) was chosen as HIP complexing agent for the
present study. SDC can potentially improve the bioavailability of insulin due to its
permeation enhancing properties (Sun et al., 2011). Also, SDC can loosen the tight
junctions in the epithelial lining, allowing for paracellular and transcellular transport
(Lindmark et al., 1998; Sakai et al., 1997).
Another approach for incorporating hydrophobicity to protein/peptide drug is solid
dispersion using anhydrous cosolvent lyophilization of drug and phospholipids.
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Phospholipids are surface-active amphiphilic compounds generated naturally in
biological membranes by action of phospholipases (Illum et al., 1989). Phospholipid is a
vital component of cell membrane with good biocompatibility/biodegradability and low
toxicity. They convert within the membrane to normal cell components (Stafford and
Dennis, 1987). At present, drug-phospholipid complex has received significant attention
due to the amphiphilic characteristic of phospholipid and the convenience, flexibility and
versatility of manufacturing process (Khan et al., 2013; Y. Li et al., 2016; Liu et al.,
2015). We have selected L-α-phosphatidylcholine (SPC) as complexing agent for this
technique as it has ability to fuse into membrane lipids, alter the membrane fluidity and
hence enhance the permeation of macromolecules at low concentration without any
membrane damage (Illum et al., 1989).
For the elucidation of nasal drug transport mechanism and the investigation of
metabolism and toxicity, diverse in vitro models of nasal cell culture systems have been
developed. RPMI 2650 cell line, Calu-3 cell line, primary human nasal epithelial cells
and passaged human nasal epithelial cells have been widely used in the nasal drug
transport study. RPMI2650 is originated from human nasal squamous cell carcinoma of
the nasal septum. However, this cell line has the following major drawbacks: no
expression of goblet or ciliated cells and no formation of confluent cell monolayers
(Kissel and Werner, 1998). The lack of monolayer formation makes this cell line
unsuitable for drug transport study. Calu-3 is from a human lung adenocarcinoma. This
cell line shows sufficient transepithelial electrical resistance (TEER) values for drug
transport studies. Calu-3 cells can develop polarized monolayers and suitable TEER
value for transport study but its origin is not from the nasal epithelium (Mathias et al.,

35

2002). The primary human nasal epithelial cell line is a promising tool for drug
permeation study, metabolism study and toxicological study. The nasal cell from primary
culture is deemed more appropriate for drug transport studies compared to other cells due
to the formation of confluent monolayers and differentiation into goblet and ciliated cells.
The human primary nasal cell system has also several limitations including difficulty in
obtaining human nasal tissue, possibility of pathogen contamination and donor to donor
variability. Serially passaged culture of human nasal epithelial cells has therefore been
introduced to overcome these limitations.
Air liquid interface (ALI) and liquid interface (LI) culture of serially passaged human
nasal epithelial cells shows musin gene expression and forms confluent monolayer, tight
junctions and ciliated cells (Cho et al., 2010). For the nasal absorption of proteins and
peptides, the paracellular route of transport which is controlled by tight junction and the
enzymatic activity (Sarkar, 1992) of the nasal epithelium are of particular interest. Apart
from the structure of the cell line, the characteristic of cell line plays a major role too.
Hence, the passaged cell culture from the primary human epithelial cells is the most
suitable in vitro cell culture model for the transport study of insulin across nasal
epithelium, which was chosen for the present study.

4.2.

Materials
Human insulin (27.5 IU/mg), Kolliphor® RH 40, Kolliphor® EL and Span® 80

were purchased from Sigma-Aldrich, Co. (St. Louis, MO, USA). Olive oil, Soybean oil,
Isopropyl palmitate, Span® 20, and Brij® 97 were purchased from Spectrum Chemical
Mfg Corp. (New Brunswick, NJ, USA). Capmul® MCM NF, Captex® PG-8 NF, Captex®
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8000 were purchased from Abitec Corporation (Janesville, WI, USA). Tween® 80 was
purchased from Amresco, Inc. (Solon, OH, USA). Labrasol and Capryol 90 were
purchased from Gattefosse (Paramus, NJ, USA). L-α-phosphatidylcholine (Soy 95%), Lα-Lysophosphatidylcholine and 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine were
purchased from Avanti Polar lipids, Inc. (Alabaster, Alabama, USA). Fluorescein
isothiocyanate isomer I, Sodium deoxycholate, HEPES, 99% and Glucose anhydrous,
99% were purchased from Alfa Aesar (Tewksbury, MA, USA). Thiazolyl blue
tetrazolium bromide, 98% was purchased from Acros Organics (Morris Plains, NJ, USA).
Analytical grade Acetonitrile and Methanol were purchased from Fisher Scientific (Fair
Lawn, NJ, USA). Dimethyl sulfoxide and Trifluoro acetic acid BDH chemicals (PA,
USA). Human nasal epithelial cells (HNEpC), Trypsin inhibitor, 0.04% Trypsin/ 0.03%
EDTA and HEPES BSS were purchased from Promo cell (Heidelberg, Germany).
Bronchial Epithelial Growth Media (BEGM) was purchased from Lonza (MD, USA).
DMEM/F-12 50/50 was purchased from Corning Cellgro (Massachusetts, VA, USA).
Penicillin Streptomycin Solution and Transwell inserts were purchased from Corning
(Oneonta, New York, USA). Fetal Bovine Serum was purchased from Atlanta
Biologicals (Flowery Branch, GA, USA). Mannitol, D-[1-14C] and Propranolol, L-[43H] were purchased from PerkinElmer (Boston, MA, USA).

Methods
Development and Characterization of Insulin Loaded Selfemulsified Nanoemulsion Formulations
Specific aims:
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•

To develop self-emulsified nanoemulsion formulations

•

To prepare and characterize lipophilic complexes of insulin

•

To evaluate cytotoxicity effects of complexing agents and formulations

•

To characterize the insulin complex-loaded nanoemulsion formulations

Development of Self-emulsified Nanoemulsion Formulations
Different ratios of the long chain (C18) and medium chain (C8) lipids with nonionic
hydrophilic and hydrophobic surfactants (Table 2) were screened to prepared o/w selfemulsified nanoemulsion formulations. The screened o/w nanoemulsion formulations
were further investigated to get different droplet size by varying the ratio of lipids to
surfactants and/ or the component of the formulation. Ideally, formulations in the size
range of 25– 400 nm were prepared. We hypothesize that small lipid droplets have a
better chance of getting absorbed intact and thus enhancing the bioavailability of insulin.
This study involved phase diagrams, droplet size measurement, polydispersity index, and
dilution test.

Phase Diagram Construction
The pseudo ternary phase diagram construction of the nanoemulsion formulation
involved a titration method in which the fixed amount of preconcentrate (lipid +
surfactant) was diluted with phosphate buffer (pH 7.4) in 10% increments. After each
addition of the phosphate buffer, the mixture was shaken in a wrist action shaker at 37o C
for 20 min and the mixture was evaluated visually to see whether clear and transparent
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nanoemulsion or white emulsion or gel is formed or it has phase separated (Prajapati et
al., 2012).

Droplet size
Droplet size and polydispersity index (PDI) were determined by a DelsaNano C
droplet size analyzer. The nanoemulsion formulations (diluted 10 times) were taken in a
plastic cuvette and were analyzed by the dynamic light scattering technique at 37o C at a
scattering angle of 90o, in triplicate (Goddeeris et al., 2006; Prajapati et al., 2012).

Dilution test
The developed nanoemulsion formulations were diluted 5, 10, 25, 50 and 100 times
with PBS and the droplet size was measured to determine the effect of dilution on the
droplet size.
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Table 2. List of materials used to develop the self-emulsified nanoemulsion formulations.
Trade Name

Composition

Soybean Oil

Long chain triglyceride (C18)

Isopropyl Palmitate

Ester of isopropyl alcohol and palmitic acid

Capmul MCM NF

Medium chain mono- and diglycerides (C8)

Capmul PG 8

Propylene Glycol Monocaprylate

Olive Oil

Long chain fatty acids (C18)

Captex 8000

Medium chain triglyceride (C8)

Cremophor EL

Polyoxl 35 castor oil, HLB 12-14

Cremophor RH 40

Polyoxyl 40 hydrogenated castor oil, HLB 14-16

Tween 80

Polyoxyethylene (20) sorbitan monooleate,
Nonionic surfactant, HLB -15

Brij 97

Polyoxyethylene 10 oleoyl ether, HLB 12.4

Labrasol

Caprylocaproyl macrogol-8 glycerides EP, HLB - 12

Span 80

Sorbitan monooleate, HLB – 4.3
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Incorporation of Lipophilicity to Human Insulin Molecule
In order to load insulin into the oil phase, it is necessary to make insulin molecule
hydrophobic. Following two methods were used to incorporate the lipophilicity to
insulin.
I. Hydrophobic Ion-paring
II. Solid Dispersion

4.3.3.1. Hydrophobic Ion-pairing
Sodium deoxycholate was used for hydrophobic ion-pairing technique. Briefly,
various amounts of sodium deoxycholate 1 mg/ml in purified water was added dropwise
manner into 5 mg of insulin solution (pH 4.0, 5.0 ml) under magnetic stirring. The
solution immediately become cloudy with some precipitation, which was insulin-sodium
deoxycholate complex (Ins-SDC) (Sun et al., 2011). The complex was collected by
centrifugation at 9000 rcf for 15 min while the free insulin still remained in the
supernatant. The resulting pellet was washed with distilled water three times by
dispersing and centrifuging. The pellet was then lyophilized and stored at -20o C until
further use. The insulin complexation efficiency (CE %) was calculated by measurement
of the concentration of free insulin in the supernatant by a high-pressure liquid
chromatography (HPLC) method, and the bound insulin fraction was calculated based on
the initial amount of insulin added. The insulin CE (%) was calculated by the following
equation:

CE (%) =

Ai – Af
Ai

X 100%

Eq. 1
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where, Ai is initial amount of insulin
Af is the free insulin present in the supernatant

4.3.3.2. Solid Dispersion
Soy-L-α-phosphatidylcholine (SPC) was used to prepare the solid dispersion of
insulin. To prepare a solvent for co-solubilization of insulin and SPC, 50 µl of glacial
acetic acid was added to 950 µl of dimethyl sulfoxide (DMSO). To this solvent, 40 mg of
SPC was added and then sonicated for 10 min to solubilize SPC. Then, 5 mg of FITCInsulin or human insulin powder was added and sonicated for another 10 min to
solubilize insulin. Such prepared clear solution was frozen for 12 h at -80o C and then
lyophilized by a Labconco lyophilizer. The lyophilized Insulin-SPC complex was stored
at -20o C until further use.
Characterization of Insulin Complexes
The complexes were characterized by differential scanning calorimetry (DSC)
and analyzed for partition coefficient in a 1-octanol/aqueous system.
4.3.4.1. Differential Scanning Calorimetry
The thermal behavior of human insulin, the complexing agents and complexes
was analyzed in a modulated differential scanning calorimeter (Q200 DSC; TA
Instruments, DE, USA) equipped with a refrigerated cooling accessory. Briefly, 4-5 mg
samples were weighed in aluminum pans and were sealed with aluminum lids. For
reference, empty sealed aluminum pan was used. The samples were heated from -20 to
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190° C at a scan rate of 5° C/min under nitrogen. Each sample was run multiple times
and representative thermograms are shown in Fig. 10.
4.3.4.2.

Partition Coefficient

Partition coefficient was analyzed by the evaluation of the distribution of insulin
in a 1-octanol/aqueous system. To 5 ml of aqueous phase (phosphate-buffered saline, pH
7.4), 5 mg of insulin powder or insulin complex was added. Five ml of 1-octanol was
added to the resultant mixture and incubated at 37o C while shaking at 300 rpm for 12 h.
The two phases were separated by centrifugation at 9,000 rcf for 10 min. Aliquots of 200
µl of the octanol and aqueous phases were diluted with 800 µl of methanol containing
0.1% (v/v) trifluoroacetic acid (TFA). The insulin concentration in both phases was
determined by HPLC. The partition coefficient was calculated by the following equation,

PC =

𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑜𝑐𝑡𝑎𝑛𝑜𝑙 𝑝ℎ𝑎𝑠𝑒
𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑎𝑞𝑢𝑒𝑜𝑢𝑠 𝑝ℎ𝑎𝑠𝑒

Eq. 2

Cytotoxic Effect of Nanoemulsion Components and
Complexing Agents on Human Nasal Epithelial Cells (HNEpC)
Viable cells with active metabolism convert MTT (3-(4, 5-dimethylthiazol-2-y;)2, 5-diphenyltetrazolium bromide) into a purple-colored formazan product with an
absorbance near 560 nm. When cells die, they lose the ability to convert MTT into
formazan, thus the color formation serves as a useful and convenient marker of only
viable cells (Riss et al., 2004). The quantity of formazan (presumably directly

43

proportional to the number of viable cells) is measured by the absorbance at 560 nm (Rao
et al., 2008a).
The cytotoxicity of complexing agents and nanoemulsion components on the
human nasal epithelial cells (HNEpC) was evaluated by the MTT colorimetric assay.
Briefly, 15000 cells in 200 µl BEGM were seeded into each well of the 96-well plates
and incubated (37o C, 5% CO2). After 48 h culture, the cells were further incubated with
200 µl of BEGM containing either different concentration of the complexing agents or
formulation components for 3 h. Then, the incubation medium was aspirated and the cells
were washed with HBSS. Fresh BEGM (180 µl) and 20 µl of MTT solution prepared in
BEGM (4.0 mg/ml) were added to each well. After 3 h of incubation, the supernatant was
discarded and formazan crystals were dissolved in 200 µl DMSO followed by vigorous
mixing for 15 min. The absorbance was determined by a microplate reader at 560 nm.
The percent viability of the cells was determined by following equation,

Cell viability = 100% - {[(AC-AT)/AC] X 100%}

Eq. 3

where, AC is the absorbance of the control well and AT is the absorbance of the treated
well.

Preparation of Insulin Loaded Self-emulsified Nanoemulsions
Insulin-SDC, Insulin-SPC, and FITC-Insulin-SPC complexes were solubilized or
dispersed in the oil phase of the nanoemulsion formulations. One g of oil mixture was
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added to the lyophilized complexes and was shaken at 200 rpm for 2 h at 37oC. If the
complex was not completely dispersed or solubilized, further amount of oil was added
until it became either a clear oily solution or homogenous dispersion.
Required amount of surfactant according to the formulation was added to
complex-loaded oil mixture and was kept for shaking for 1 h at 300 rpm and 37o C. One g
of the complex-loaded preconcentrate was diluted further with PBS to form
nanoemulsion and was shaken for 1 h at 300 rpm and 37oC.
The complex-loaded nanoemulsion formulations were characterized for droplet
size, polydispersity index, and leakage of insulin from the oil phase to the aqueous phase.

4.3.6.1.

Droplet Size

The nanoemulsion with insulin loaded in the oil phase were evaluated for droplet
size by a DelsaNano C droplet size analyzer and the droplet size of the blank
nanoemulsions with insulin solubilized in aqueous phase was also analyzed.

4.3.6.2.

Leakage of Insulin from the Oil Phase

The leakage of the insulin from the oil phase into the aqueous phase of the
nanoemulsion was studied by the membrane filtration method (Khatri and Shao, 2017a).
Ten ml of the nanoemulsion was added to a Centriprep® 30K tube and centrifuged at
1,500 g for 10 min. Insulin concentration in the filtrate collected after centrifugation was
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analyzed by HPLC and compared to the insulin concentration in the nanoemulsion before
centrifugation to calculate the leakage of insulin from the oil phase.

Transport of Insulin by Nanoemulsion through Human Nasal
Epithelial Cell Monolayer
Specific aim:
•

To study the transport of insulin by the nanoemulsion system through human
nasal epithelial cell monolayer.

4.3.7.1.

HNEpC Transport Study

Briefly, cryovial from the liquid nitrogen container was removed and immediately
placed on dry ice – even for short transportation. Under a laminar flow bench, cap of the
cryovial was twisted quarter turn to release the pressure, then re-tightened. Vial was then
immersed into a water bath (37o C) just up to the screw cap for 2 min. It was ensured that
no water entered the thread of the screw cap. The vial was disinfected with 70% v/v
ethanol under a laminar flow bench. The cells were seeded at 10,000 cells/cm2 in a cell
culture flask containing the pre-warmed growth medium (BEGM). The flask was placed
in an incubator at 37o C with 95% humidified air and 5% CO2. The culture media was
replaced after 16-24 h and then every other day (Schmidt et al., 1998).
Once the cells reached 70-80 % confluency, the cells were detached by the detach
kit from Promocell and cells were further seeded on a Transwell inserts at a density of
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5×105 cells/cm2. The apical and basolateral side of the transwells were filled with 0.3 ml
and 1.0 ml of cell culture media respectively. Media of both sides were changed after the
first 24 h and then every other day. The remaining detached cells were further
subcultured for the next passage at a density of 10,000 cells/cm2, and the growth medium
was changed every other day.
The transepithelial electrical resistance (TEER) value of the transwell inserts was
measured by an EVOM voltohmmeter device, and the transwell inserts with TEER values
higher than 300 Ω·cm2 were chosen for the transport study. Transport medium was HBSS
(Hank’s Balanced Salt Solution) supplemented with 15 mM glucose and 15 mM HEPES
buffer, pH 7.4 (Lin et al., 2007, 2005). Prior to each experiment, the monolayers were
washed with a pre-warmed transport medium, and were allowed to equilibrate for 20 min
in the incubator with 0.3 ml of transport media on the donor side and 1.0 ml of transport
media in receiver side. Then, the transport media in donor side was replaced with 0.3 ml
of formulations prepared in transport medium to evaluate the permeation from apical to
basolateral direction. Aliquots of 200 µl were withdrawn from the basolateral
compartment at pre-determined time points (30, 60, 90, 120 and 180 min). Aliquots were
assayed for fluorescence using plate reader to quantify the permeated FITC labeled
insulin. The % transport was calculated.
In vitro transport and monolayer integrity studies were carried out for following
formulations:
•

FITC-Insulin-SPC complex loaded in oil phase of nanoemulsion

•

FITC-Inulin solubilized in aqueous phase (transport media) of blank
nanoemulsion
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•

FITC-Insulin-SPC complex dispersed in transport media, pH 7.4

•

FITC-Insulin Solution in transport media, pH 7.4

4.3.7.2.

HNEpC Monolayer Integrity Study

Propranolol, L-[4-3H] and Mannitol, D-[1-14C] were used as transcellular and
paracellular markers, respectively (Rao et al., 2008a). HNEpC monolayer was formed as
described in the transport study (previous section 4.3.7.1.). Once the TEER values were
higher than 300 Ω·cm2, 0.3 ml of formulations prepared with transport media containing
0.5 μCi/ml of Propranolol and 0.03 μCi/ml of Mannitol were added on the donor side and
1 ml of transport media was added on the basolateral side of the transwell inserts. The
monolayer was incubated for 3 h at 37oC with 5% CO2 and 95% air. Aliquots of 200 µl
were withdrawn from the basolateral compartment at pre-determined time points (30, 60,
90, 120 and 180 min) and replaced with fresh 200 μl of transport media. The samples
were assayed for Propranolol, L-[4-3H] and Mannitol, D-[1-14C] by radioactivity
measurement. Aliquoted 100 µl samples were mixed with 3 ml of scintillation cocktail
and the disintegrations per min (dpm) was counted by a Tri-carb Liquid Scintillation
Analyzer Model B3110 TR (PerkinElmer, Shelton, CT, USA).

Data Analysis
The values were expressed as mean ± S.D. Statistical analysis was performed by
student’s t-test. A value of p < 0.05 was considered to be statistically significant.
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4.4.

Results

Formulation Development
Self-emulsified nanoemulsions are thermodynamically stable, single-phase,
translucent or opalescent liquid systems composed of an oil or oil mixture and a
surfactant or surfactant mixture which forms oil in water nanoemulsion upon addition of
water with gentle agitation.
Nanoemulsion formulations were developed by first screening six oils and six
surfactants listed in Table 2. in various ratios with PBS. Formulations which formed clear
or translucent systems with droplet size less than 150 nm were characterized as
nanoemulsions. Phase diagrams with nanoemulsion regions were considered for
formulation development study.
In our study, medium chain lipids capmul MCM and captex 8000 with cremophor
RH40 and cremophor EL showed a clear (nanoemulsion) region (Fig. 8). To increase the
naonoemulsion region these two oils were mixed in various ratios and were evaluated for
nanoemulsion formation with cremophor RH40 as surfactant and PBS (Table 3.).
Formulations NE-3, NE-5, NE-6, NE-8, and NE-9 showed droplet size less than 50 nm
when diluted 10 times with PBS. Whereas, formulations NE-1, NE-2, NE-4 and NE-7
showed droplet size higher than 100 nm with 10 times dilution. Nanoemulsions (NE-1 to
NE-9) were further investigated for effect of dilution on droplet size and results are
shown in Table 4. It was observed that formulations with droplet size higher than 100 nm
had effect of dilution on droplet size. Whereas, formulations with droplet size less than
50 nm had no effect of dilution on droplet size. These formulations were further
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evaluated for toxicity on human nasal epithelial cells to select a nanoemulsion with least
possible toxic effects on cells.
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Fig. 8. Phase diagram of Captex 8000: Cremophor EL: PBS and Capmul MCM:
Cremophor RH40: PBS.
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Table 3. Formulation composition, droplet size and polydispersity index (PDI) at 10
times dilution with PBS (mean ± S.D., n=3).

NE-1

Capmul
MCM:
Captex 8000
7:3

Oil Mix:
Cremophor
RH40
7:3

NE-2

7:3

NE-3

Formulation
Name

Droplet Size
(nm)

PDI

714.3 ± 45.0

0.374 ± 0.04

6:4

447.3 ± 89.6

0.366 ± 0.06

7:3

5:5

28.8 ± 4.1

0.244 ± 0.16

NE-4

6:4

7:3

543.7 ± 432.0

0.356 ± 0.0.

NE-5

6:4

6:4

33.8 ± 1.8

0.212 ± 0.06

NE-6

6:4

5:5

35.3 ± 9.9

0.139 ± 0.13

NE-7

5:5

7:3

115.7 ± 133.4

0.285 ± 0.13

NE-8

5:5

6:4

36.1 ± 3.4

0.243 ± 0.04

NE-9

5:5

5:5

29.5 ± 1.7

0.208 ± 0.06
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Table 4. Effect of dilution with PBS on droplet size of the formulations (mean ± S.D.,
n=3).

Dilution Times with PBS
Formulation
Name

10

25

50

100

NE-1

714.3 ± 45.0

387.8 ± 17.7

151.5 ± 12.2

42.4 ± 2.9

NE-2

447.3 ± 89.6

148.1 ± 14.8

31.5 ± 1.5

32.7 ± 0.5

NE-3

28.8 ± 4.1

26.4 ± 2.1

24.5± 0.6

25.9 ± 0.4

NE-4

543.7± 432.0

78.8 ± 24.4

60.5 ± 24.8

44.4 ± 2.2

NE-5

33.8 ± 1.8

31.7 ± 2.3

31.5 ± 3.5

31.9 ± 3.4

NE-6

35.3 ± 9.9

27.4 ± 1.0

28.7 ± 1.0

29.0 ± 0.5

NE-7

115.7 ± 133.4

148.7 ± 69.4

90.1 ± 19.4

78.1 ± 3.6

NE-8

36.1 ± 3.4

35.8 ± 4.3

36.1 ± 1.9

36.7 ± 1.6

NE-9

29.47 ± 1.70

30.97 ± 3.64

30.5 ± 1.2

30.4 ± 1.0
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Preparation of Insulin Complexes
Insulin being a hydrophilic molecule, has very poor solubility in hydrophobic organic
solvents and lipids. However, with hydrophobic ion-pairing and solid dispersion
methods, it is possible to load insulin into lipid-based drug delivery systems.
4.4.2.1. Hydrophobic Ion-pairing
Insulin has six basic groups and six acidic groups with an isoelectric point of 5.35
– 5.45 (Dai and Dong, 2007). It is positively charged below the isoelectric point (due to
two histidine, one lysine, one arginine, and two N-terminal amino acid residues). Sodium
deoxycholate (SDC) being an anionic surfactant (pKa 6.3) forms a complex (Ins-SDC)
with insulin at pH 4.0 by ionic interaction. As shown in Fig. 9, increasing the molar ratio
of SDC:Insulin increased the complexation efficiency (CE). Maximum CE was achieved
when the molar ratio was 6:1, as SDC has one negative charge and insulin can have six
positive charges when all the basic groups are ionized. Therefore, 6:1 molar ratio of
SDC:Insulin was used for further studies. These results were in agreement with
previously published data by Sun et al. (Sun et al., 2011).
Sun et al. studied the net surface charge of Ins-SDC complex and reported that it
was positive up to molar ratio 6:1 due to surplus positively charged insulin and it became
nearly zero for molar ratio 6:1. Further addition of sodium deoxycholate above 6:1 molar
ratio gave negative net surface charge due to higher amount of SDC present in complex
(Sun et al., 2011).
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Fig. 9. Complexation efficiency (%) vs molar ratio of sodium deoxycholate (SDC) to
Insulin (mean ± S.D., n=3).
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4.4.2.2. Solid Dispersion
SPC, being an amphiphilic molecule, has been widely used to improve the solubility
and bioavailability of drugs (Xie et al., 2017). Ins-SPC complex was prepared by
anhydrous co-solvent lyophilization process. Both insulin and SPC were dissolved in
acidified DMSO, and then lyophilized. Since DMSO is an aprotic polar solvent with
great biocompatibility and dissolvable capacity for many substances, it has been
generally utilized as protein dissolving agent during the process of supercritical
antisolvent precipitation (Winters et al., 1996).
Increasing the molar ratio of SPC to insulin increases the transmittance of organic
solvent system gradually. Cui et. al. studied the transmittance of the Ins-SPC complex
solubilized organic solvent systems and observed that transmittance of the system
reached to 100% when molar ratio 60:1 of SPC:Insulin was used which indicated that
insulin was completely solubilized in organic solvent (Cui et al., 2006). Therefore, in
order to achieve maximum lipophilicity, molar ratio of 60:1 and weight ratio of 8:1 of
SPC:Insulin was used to prepare the complex. Porous complex was obtained when the
complex solution was lyophilized at -540 C for 12 h. It formed a thin and dry gel like
waterless layer which was further evaluated for complex formation and was loaded into
the nanoemulsion system.
Characterization of Insulin Complexes
4.4.3.1.

Differential Scanning Calorimetry

The results of differential scanning calorimetry are presented in Fig. 10.
Thermograms of insulin showed no specific events, indicating that insulin was in
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amorphous form. Whereas, SDC showed a sharp exothermic peak around 175o C and two
broad tiny peaks around 120o C and 140o C, indicating that SDC was in crystalline form.
However, Ins-SPC complex thermogram indicates that the complex was in amorphous
form and SDC lost its crystalline characteristics when complexed with insulin.
SPC thermogram showed a wide exothermic peak around 160 oC, which might be
due to degradation. Ins-SPC complex was observed to be amourphous with Tg of 100 oC.
The above DSC results confirmed that complexes were formed and both the
complexes were in amorphous form.
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Fig. 10. Representative thermograms of insulin, complexing agents (SDC and SPC), InsSDC complex and Ins-SPC complex.
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4.4.3.2.

Partition Coefficient

In order to determine the incorporation of lipophilicity to the insulin molecule, the
partition coefficient of insulin, Ins-SDC complex and Ins-SPC complex in 1Octanol/Aqueous system was determined. The partition coefficient of insulin, Ins-SPC
and Ins-SDC complex was determined to be 0.07 ± 0.04, 0.73 ± 0.15, and 0.53 ± 0.21,
(mean ± S.D., n=3) respectively (Fig. 11). The two complexes increased the partition
coefficient about 8-10 times. Such significant increase in partition coefficient values
indicated that lipophilic complexes of insulin were formed.
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Fig. 11. Partition coefficient of insulin and insulin complexes (mean ± S.D., n=3).
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Cytotoxicity of Formulation Components and Complexing
Agents on Human Nasal Epithelial Cells (HNEpC)
In order to develop a formulation with least toxicity effect on human nasal
membrane, cytotoxicity of the complexing agents, surfactant and formulation on human
nasal epithelial cells was carried out by MTT assay.
SDC had an effect on the viability of human nasal epithelial cells. As shown in
Fig. 12A, increase in concentration of SDC from 0.1% to 10% decreased the viability of
HNEpC. At lowest concentration of 0.1% of SDC, the viability was observed to be 43.59
% ± 6.91 %.
SPC did not have any significant effect on viability of HNEpC. Concentration of
0.1% to 10% of SPC were used for the cytotoxicity study and it was observed that even at
10% concentration, the cell viability was 88.90 % ± 15.12 % (Fig. 12B). It was concluded
from this study that SPC was much safer compared to SDC as it showed no toxic effect
on the cells. Hence further experiments were carried out with SPC as the complexing
agent.
Surfactant Cremophor RH40 shows concentration-dependent effect on the cell
viability. As shown in Fig. 13, when the Cremophor RH40 concentration increased from
0.1% to 10%, the cell viability decreased from 100% to about 40%. The cell viability was
81.36 % ± 18.51 % at 1% Cremophor RH40. Hence, cremophor RH 40 was found to be
least toxic below concentration of 1%.
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Formulations NE-1 to NE-9 were evaluated at different dilutions for cytotoxicity,
and the results are depicted in Fig. 14. The viability of HNEpC increased as the number
of dilutions increased. All the formulations were observed to be toxic at 10- and 25-times
dilutions with PBS (Fig. 14A), resulting in about 10% cell viability. When the
formulations were diluted 50 times, NE-8 and NE-9 resulted in over 80% cell viability,
whereas, the other formulations exhibited lower than 45% cell viability (Fig. 14B). At 50
times dilution, RH 40 concentration was 1% or lower for all formulations. Since RH40
alone showed more than 80% viability at 1% or lower concentration, this cytotoxicity
effect (less than 5% viability) could be due to the toxic effect of lipids. Capmul MCM
and Captex 8000 were used in various ratios to prepare the lipid mixture. Capmul MCM
concentration decreased in the formulations from NE-1 to NE-9, and the cell viability had
increased from NE-1 to NE-9. Similar trend was observed at 100 times dilution.
Therefore, NE-8 and NE-9 were considered to be less toxic as compared to other
formulations and were used for further studies.
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Fig. 12. Effect of the complexing agents A) SDC and B) SPC on the viability of human
nasal epithelial cells after 3 h exposure in vitro (mean ± S.D., n=6).
63

Fig. 13. Effect of surfactant Cremophor RH40 on the viability of human nasal epithelial
cells after 3 h exposure in vitro (mean ± S.D., n=6).

64

% Viability of HNEpC

A. Cytotoxicity of Formulations
100
90
80
70
60
50
40
30
20
10
0
10

25
Number of Dilutions

NE-1

NE-2

NE-3

NE-4

NE-5

NE-6

NE-7

NE-8

NE-9

B. Cytotoxicity of Formulations
140

% Viability of HNEpC

120
100
80
60
40
20
0
50

100
Number of Dilutions

NE-1

NE-2

NE-3

NE-4

NE-5

NE-6

NE-7

NE-8

NE-9

Fig. 14. Effect of various nanoemulsions on the viability of HNEpC at: A) 10- and 25-;
B) 50- and 100-times dilutions (mean ± S.D., n=6).
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Preparation of Insulin Complex Loaded Nanoemulsion

The solubility/dispersibility of Ins-SDC and Ins-SPC complexes in medium chain
lipid mixture (Capmul MCM: Captex 8000 = 1:1) was tested and the results are shown in
Table 5. Ins-SDC complex was not dispersed at the lowest concentration (0.1%) and this
could be due to its salt like properties. Whereas, Ins-SPC complex was dispersed and
translucent oil mixture was achieved within the concentration range of 0.1-0.8%. Further
studies were carried out on Ins-SPC complex only because Ins-SDC complex was more
toxic and less dispersible in lipid mixture than Ins-SPC complex.
The pseudo ternary phase diagram of the 1:1 lipid mixture of capmul
MCM:captex 8000 with Cremophor RH40 are depicted in Fig. 15. Nanoemulsion region
covers a wide range which indicates that this system can form nanoemulsion with various
amount of buffer/water.
The preconcentrate for NE-8 contains 60% of the lipid mixture, and NE-9
contains 50%. More insulin was loaded in NE-8 as compared to NE-9. Therefore, InsSPC complex was loaded into the lipid mixture of capmul MCM and captex 8000 (1:1) at
the concentration of 0.8%, and then mixed with Cremophor RH40 at 6:4 ratio to form
insulin-loaded NE-8 preconcentrate. And nanoemulsions prepared from this
preconcentrate were used for further studies.

4.4.5.1.

Droplet size of Ins-SPC Loaded NE-8 Nanoemulsion

Droplet size of Ins-SPC complex loaded NE-8 nanoemulsion was found to in the
range of 25 nm to 50 nm when diluted from 5 to 100 times with PBS (Table 6). No
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significant difference was observed in droplet size between the blank and the complexloaded nanoemulsions. Droplet size of blank NE-8 nanoemulsion (5 times dilution) with
insulin solubilized in the aqueous phase was determined to be 32.2 ± 2.0 and PDI was
determined to be 0.250 ± 0.07.

4.4.5.2.

Leakage of Insulin from the Oil Phase to the Aqueous Phase of

the Nanoemulsion
Leakage of insulin from the complex-loaded oil phase to the aqueous phase of
NE-8 nanoemulsion was determined by the membrane centrifugation method with
Centriprep 30K tubes (molecular weight cut off: 30,000 Da). Lipid droplets in the
nanoemulsion are relatively large, and cannot pass through the membrane, and retains in
the donor compartment of the tube, whereas, insulin present in the aqueous phase gets
filtered to the receiver compartment as the molecular weight of insulin is 5808 Da which
is much lesser than the cut off weight of the membrane. The collected filtrate in the
receiver compartment was analyzed for insulin concentration. The insulin concentration
in the filtrate was compared to the insulin concentration in the preparation to calculate the
percentage leakage, and the results are shown in Table 7. Less than 20% of leakage of
insulin from oil phase to aqueous phase was observed for complex-loaded NE-8
nanoemulsion.

67

Table 5. Dispersibility of insulin complexes in the lipid mixture of Capmul MCM and
Captex 8000 (1:1).

Complexed
Insulin/Lipid Mixture
(mg/g)

Ins-SDC Complex

Ins-SPC Complex

10

Not dispersed

Partially dispersed

9

Not dispersed

Partially dispersed

8

Not dispersed

Completely Dispersed

7

Not dispersed

Completely Dispersed

6

Not dispersed

Completely Dispersed

5

Not dispersed

Completely Dispersed

4

Not dispersed

Completely Dispersed

3

Not dispersed

Completely Dispersed

2

Not dispersed

Completely Dispersed

1
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Fig. 15. Pseudo-ternary phase diagram.
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Table 6. Droplet size of NE-8 nanoemulsions with and without Ins-SPC complex loaded
in the oil phase (mean ± S.D., n=3).

No. of Dilutions with
PBS

Blank NE-8
Nanoemulsion

Ins-SPC Complex
Loaded NE-8
Nanoemulsion

5

37.9 ± 5.7

42.8 ± 7.0

10

36.7 ± 3.4

34.6 ± 4.8

25

35.8 ± 4.3

32.8 ± 3.8

50

36.1 ± 1.9

33.4 ± 3.9

100

36.7 ± 1.6

34.6 ± 3.5
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Table 7. Leakage of insulin from various preparations (mean ± S.D., n=3).
Name

Leakage (%)

Insulin solution

92.2 ± 6.4

Ins-SPC complex loaded NE-8

17.4 ± 2.8
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Transport of Insulin through Human Nasal Epithelial Cell
Monolayer
To predict the absorption of insulin through nasal membrane in vivo by the
nanoemulsion system, FITC-Ins-SPC complex-loaded NE-8-50X (50 times diluted with
transport medium) nanoemulsion along with controls was tested for the transport across
human nasal epithelial cell monolayer in vitro. NE-8-50X nanoemulsion was selected for
transport study as it showed acceptable cytotoxicity (Fig. 14B) and the transported
amount of FITC-Insulin was in detectable range.
The transport results are presented in Fig. 16. The transport of insulin by the
nanoemulsion system was significantly (p < 0.00005) higher than the FITC-Insulin
solution, indicating that the nanoemulsion system enhanced the permeability of insulin
across HNEpC monolayer. To further investigate whether the enhanced permeation was
due to the complexing agent or the nanoemulsion components, FITC-Insulin-SPC
complex in buffer and blank NE-8 (without complex) nanoemulsion with FITC-Insulin in
its aqueous phase were evaluated for transport. Both the complex suspension and blank
NE showed increased transport as compared to the insulin solution. The permeation
enhancement by the blank NE-8 with insulin in aqueous phase was significantly (p <
0.05) higher than the complex suspension, which indicates that formulation components
could have imparted the permeation enhancing effects.
Moreover, the complex-loaded NE-8-50X nanoemulsion presented significantly
(p<0.05) higher transport than the blank NE-8-50X nanoemulsion. It can be interpreted
from these results that loading insulin inside the oil phase enhances the permeation across
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HNEpC monolayer through possible transcellular absorption together with paracellular
permeation.
Previously, Rao. et al. and Khatri et. al. have reported that enhanced transport of
macromolecules from nanoemulsions could be due to the transport of lipid nano-droplets
through epithelial cell monolayer (Khatri and Shao, 2017b; Rao et al., 2008a). Therefore,
to evaluate the transport of lipid droplets, the droplet size was measured in the donor and
receiver side at the end of transport study to confirm the transport of lipid nano-droplets
through human nasal epithelial cell monolayer (Table 8). Droplet size in the donor or
receiver chamber was not detected in case of FITC-Insulin solution. For the complex
suspension, droplet size of about 1000 nm was observed in the receiver chamber which
indicates phosphatidylcholine present in complex may have interacted and fused through
the cells or through the tight junctions. Complex loaded nanoemulsion NE-8-50X showed
higher droplet size in the receiver chamber than the donor chamber which could have
been due to the presence of phosphatidylcholine. Blank nanoemulsion also showed
slightly higher droplet size indicating that the droplets when passing through cell
membrane may have interacted with cell components and may have transported to the
receiver side.
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Fig. 16. Permeability of complex loaded nanoemulsion, blank nanoemulsion with insulin
in aqueous phase, complex suspension and insulin solution through HNEpC monolayer,
(mean ± S.D., n=6).
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Table 8. Droplet size in the donor and receiver side at the end of the transport study
through HNEpC monolayer (mean ± SD, n ≥ 5).

Droplet Size (nm)
Formulation

Donor Side

Receiver side

FITC-Insulin solution

ND

ND

Complex suspension

4057.5 ± 2190.7

1023.9 ± 168.5

FITC-Ins-SPC complex-loaded NE-8
nanoemulsion

36.6 ± 2.6

114.4 ± 39.8

Blank NE-8 nanoemulsion with FITCInsulin in aqueous phase

37.8 ± 3.6

51.2 ± 7.6

ND: Not detected
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Effect of the NE-8 Nanoemulsion on the Integrity of the
HNEpC Monolayer
To evaluate the impact of the formulation on the integrity of the human nasal
epithelial cell monolayer, permeability of the paracellular marker and transcellular
marker in presence of NE-8-50X nanoemulsion and other controls was studied.
Propranolol undergoes passive transcellular transport as it is a lipophilic (Log P
2.53) molecule with molecular weight of 259.3 g/mol. Mannitol transports through
passive paracellular transport as it is a highly hydrophilic molecule (Log P -2.5) with low
molecular weight of 182.2 g/mol (Kaushal et al., 2006). Therefore, propranolol and
mannitol have been used as the transcellular and paracellular marker, respectively, to
determine the integrity of the cell monolayers.
As shown in Fig. 17, there was no significant difference in the transport amongst
Ins-SPC complex-loaded NE-8-50X nanoemulsion and blank NE-8-50X with insulin in
aqueous phase and insulin solution. These results indicate that the monolayer’s integrity
was maintained throughout the transport study. The cumulative transport of propranolol
at 3 h decreased significantly in presence of Ins-SPC complex suspension (p < 0.005)
compared to the other three cases. It could be because of SPC which may have hindered
the transport of propranolol by creating a viscous layer on top of the monolayer.
The transport of the paracellular marker mannitol is depicted in Fig. 18. Results
showed that mannitol’s permeability after 3 h of cumulative transport didn’t change
significantly for NE-8 formulation and blank NE. However, mannitol’s transport
significantly deceased (p < 0.05) in presence of complex suspension. Again, this could be
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due to viscous nature of SPC. Results indicate that cell monolayer was intact throughout
the study and the enhanced permeability was not due to cell damage.
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Fig. 17. Permeability of Propranolol through HNEpC monolayer (mean ± S.D., n=6).
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Fig. 18. Permeability of Mannitol through HNEpC monolayer (mean ± S.D., n=6).
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4.5.

Conclusion
Lipophilic complexes of insulin and insulin loaded nanoemulsions were successfully

developed and characterized. Ins-SPC complex loaded nanoemulsion with acceptable
toxicity enhanced the permeation of insulin by three times as compared to insulin
solution.
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CHAPTER 5. IN-VIVO ANIMAL STUDY

Introduction
Various animal models have been used for intranasal delivery of insulin. From small
animals such as guinea pigs, hamsters, mice and rats to big animals such as rabbits, dogs,
monkeys and sheep. Although big animals are preferred over small animals for their large
nasal cavity which can allow more delivery volume, they are expensive to use. Rats are
often used as the animal model for in vivo study as it is easy to handle, inexpensive and
provides sufficient volume of blood for pharmacokinetic studies (Ehrhardt and Kim,
2008; Gizurarson, 1990). Moreover, rat and human nasal cavity have similar anatomical
features, nasal cavity is divided into two main air passages by the nasal septum
(Chamanza and Wright, 2015).
Insulin deficiency in diabetic rats causes extreme changes in metabolism, a reduction
in liver protein synthesis, dehydration, decreased activity of the sympathetic nervous
system, and osmotic diuresis (Anwana and Garland, 1991; Yoshida et al., 1985). Also,
streptozotocin-induced diabetic rats show a different response profile to environmental
stress factors (Bellush and Henley, 1990). Linn et. al. studied the intranasal absorption of
insulin in diabetic and non-diabetic rats and observed increased variability of blood
glucose levels in the diabetic rats as compared to healthy rats (Simon et al., 2005).
Therefore, in order to minimize the variability in blood glucose levels due to
physiological changes in diabetic rats, we have selected healthy rat as an animal model
for our study.
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Specific objectives of the study:
•

To determine whether insulin loaded in the oil phase of nanoemulsion can
enhance intranasal absorption of insulin

•

To evaluate the toxicity effect of formulation components on nasal membrane

Materials
Human insulin (27.5 IU/mg) was purchased from Sigma-Aldrich, Co. (St. Louis,
MO, USA). L-α-phosphatidylcholine (Soy 95%) was purchased from Avanti Polar
Lipids, Inc. (Alabama, USA). AimStrip® Plus Glucose meter was purchased from
ERMAINE LABORATORIES, INC (San-Antonio, TX, USA). Human Insulin ELISA
Kit was purchased from Crystal Chem (Elk Grove Village, IL, USA). Lithium heparin
tubes were purchased from SARSTEDT AG & Co. (Nümbrecht, Germany). Stainless
steel disposable scalpels were purchased from Intergra York PA, Inc (PA, USA).
Lidocaine Hydrochloride Jelly USP, 2% was purchased from Akron, Lake Forest (IL,
USA). Animal feeding needles were purchased from Cadence Science, Inc. (Plainfield
Pike Cranston, RI, USA). Isoflurane, USP was purchased from HENRY SCHEIN
(Dublin, OH, USA). Sterile gauze sponges were purchased from Dukal Corporation
(Ronkonkoma, NY, USA).
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Methods
Animal Study Procedure
Male Sprague Dawley rats weighing 280-400 gram were used for this study. The rats
were randomly divided into six groups with six rats in each group (Table 9). The rats
were fasted for 12 h prior to experiment with water ad libitum. The rats were anesthetized
by 3% isoflurane. Once anesthetized, the rats were taken out of the isoflurane chamber
and were kept in a supine position on a soft-temp reusable veterinary heating pad with
nose cone attached to deliver 2% isoflurane for maintenance of unconscious effect.
The rats were anesthetized for 30 min before dosing to stabilize the blood glucose
level and the blood glucose was measured every 5-10 min. Effect of anesthesia on blood
glucose level was evaluated by monitoring anesthetized rat’s blood glucose level for 4 h
without administering any formulation. One ml of 20% glucose was given by
intraperitoneal injection if the blood glucose level dropped below 30 mg/dL while
performing the study (Mcnay et al., 2013).
For intranasal delivery, 3.6 IU/kg of human insulin in about 50 µl of various
formulations was administered to the nasal cavity via the right nostril by a micro syringe
connected to a polyethylene tubing which was inserted about 0.6 cm into the nostril. For
subcutaneous delivery, 1 IU/kg human insulin in about 500 µl buffer (PBS, pH 7.4) was
given at loose skin over the back muscle. Blood samples (100 – 200 µl, depending on
rat’s body weight) were collected by tail tipping into heparin coated microcentrifuge
tubes immediately before dosing and at 5, 15, 30, 45, 60, 90, 120, 180 & 240 min after
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the administration. The blood glucose level was measured using AimStrip® Plus Blood
Glucose Meter each time the blood was collected and noted. The blood samples were
centrifuged at 9000 rcf for 10 min at 4o C and the plasma was collected. The plasma
samples were stored at -20o C until further analysis. Plasma concentration of insulin was
determined by ELISA (Enzyme-linked immunosorbent assay). Standard noncompartmental analysis was performed for determination of the pharmacokinetic
parameters
All the rats were euthanized by carbon dioxide (CO2) right after the experiment was
completed. After euthanasia, the head of the rat was collected and stored in 10% formalin
solution for the histology study on the nasal membrane.
ELISA Assay
The insulin ELISA kit used for sample analysis was specific to human insulin and
didn’t react with rat’s inherent insulin present in plasma. ELISA kit used was designed on
a principle of sandwich assay by utilizing a specific antibody immobilized onto the
microplate wells and an antibody labeled with HRP enzyme.
ELISA Assay procedure
All reagents were brought to room temperature for at least 30 min prior to running
the assay. In each well of a 96-well microplate, 100 µl of working HRP labeled antibody
followed by 25 µl of plasma sample or kit’s standard was added and mixed well by
repeated pipetting. Microplate was sealed with sealer and incubated at 37o C for 2 h. The
contents were aspirated from the wells after incubation and the wells were washed three
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times using 300 µl wash buffer. After each wash, any remaining solution in the well was
removed by inverting and tapping the plate firmly on a clean paper towel. After washing,
100 µl of the substrate solution was added to each well and incubated in dark for 15 min
at room temperature. Reaction was stopped by adding 100 µl of the stop solution.
Absorbance (A450) was measured by a plate reader. A standard curve with the kit’s
standards and the concentration of insulin in plasma samples was calculated according to
standard curve.
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Table 9. Animal groups for the in-vivo study.
Animal Group # Treatment
1

Buffer (PBS) without insulin, 50 µl, intranasal

2

Insulin solution (PBS), 3.6 IU/kg, 50 µl, intranasal

3

4

5

6

Ins-SPC complex loaded in the oil phase of NE-8-5X, 3.6 IU/kg,
50 µl, intranasal
Ins-SPC complex suspension, 3.6 IU/kg, 50 µl, intranasal
Blank NE-8-5X with insulin solubilized in aqueous phase, 3.6
IU/kg, 50 µl, intranasal
Insulin buffer solution by subcutaneous route, 1 IU/kg, 500 µl,
subcutaneous
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Histological Study
Histological examination was carried out to determine any toxic effect of the
formulations on nasal membrane by the examination for any signs of epithelial
disorganization, cilia disappearance and slight dysplastic changes.
Three animals from each group of nasal administration were evaluated for histology
study. The nasal cavity tissue was collected, decalcified and was dehydrated with 100%,
95%, 80%, 70% alcohol. The resulting blocks were embedded in paraffin and thin crosssections of samples were prepared on a microtome and stained with hematoxylin-eosin
for light microscopic observation (Piao et al., 2010).
Data Analysis
For data analysis, all the values were expressed as mean ± S.D. or SEM. Statistical
analysis was performed by student’s t-test. A value of p < 0.05 was considered to be
statistically significant.
Results
In-vivo Absorption Study
For in-vivo absorption study, insulin dose (3.6 IU/kg) was decided based on
previously published reports and expected pharmacological activity. In order to deliver
3.6 IU/kg of insulin, NE-8 preconcentrate was diluted 5 times with PBS (NE-8-5X).
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Some of the rats had died during the study due to lack of animal study experience and
device/technical issues related to anesthesia system. Hence, we had used 3 rats/group for
complex suspension and insulin solution groups and 6 rats/group for subcutaneous
injection, Ins-SPC complex loaded NE-8-5X and blank NE-8-5X with insulin in aqueous
phase.
From the study on effect of anesthesia on blood glucose level, it was observed that
glucose level remained between 95% -100% during the entire study time (data not
shown). This confirmed the absence of anesthesia effect on glucose level.
Hypoglycemic effect after dosing of various formulations is depicted in Fig. 19, and
the pharmacodynamic parameters are presented in Table 10. Subcutaneous delivery of 1
IU/kg insulin reduced maximum blood glucose levels by approximately 52%. Area above
the curve for SC delivery was used as reference for calculating the relative
pharmacological availability (PA) of nasally administered insulin. PA was calculated by
following equation:
𝐴𝐴𝐶𝑓(0−240𝑚𝑖𝑛) /𝐷𝑜𝑠𝑒𝑖𝑛

% 𝑃𝐴 = 𝐴𝐴𝐶

𝑠𝑐 (0−240𝑚𝑖𝑛) /𝐷𝑜𝑠𝑒𝑠𝑐

X 100

Eq. 4

where, AACf is area above the curve of glucose reduction-time curve of formulation or
buffer group; AACsc is area above the curve of glucose reduction-time curve of
subcutaneous injection group, Dosein is intranasal delivery dose and Dosesc is
subcutaneous delivery dose.
Insulin solution and buffer (PBS, pH 7.4) without drug showed similar response of
glucose level with the maximum glucose reduction of approximate 20%. The PA of
88

buffer and insulin solution group was observed to be 11.8 ± 1.4 and 13.1 ± 2.3,
respectively. Ins-SPC complex suspension (prepared in buffer PBS), insulin in aqueous
phase of blank NE-8-5X and Ins-SPC complex loaded NE-8 showed up to 40%, 60% and
70% maximum glucose reduction with mean relative PA of 23.5 ± 2.9, 30.1 ± 4.1 and
36.2 ± 3.6, respectively.
The plasma insulin concentration vs time profile and pharmacokinetic parameters are
shown in Fig. 20 and Table 10, respectively. Subcutaneous administration of insulin
solution presented Cmax of 77.6 ± 9.2 µU/ml and AUC0-240min of 77.1 ± 12.6 (µU * h/ml).
This AUC value of subcutaneous delivery was used as a reference for the calculation of
the relative bioavailability (BA) of the intranasally administered insulin. BA was
calculated by following equation:
𝐴𝑈𝐶𝑓 (0−240𝑚𝑖𝑛) /𝐷𝑜𝑠𝑒𝑖𝑛

% 𝐵𝐴 = 𝐴𝑈𝐶

𝑠𝑐 (0−240𝑚𝑖𝑛 )/𝐷𝑜𝑠𝑒𝑠𝑐

X 100

Eq. 5

where, AUCf is area under the insulin-time curve of formulation or buffer group; AUCsc
is area under the curve of insulin-time curve of subcutaneous injection group, Dosein is
intranasal delivery dose and Dosesc is subcutaneous delivery dose.
The intranasal administration of insulin solution showed minimal absorption (Fig. 20)
with Cmax of 5.8 ± 1.9 µU/ml and the bioavailability of 5.5 ± 1.4 %. The administration of
Ins-SPC complex suspension resulted in small elevation of plasma insulin concentration
with Cmax of 12.9 ± 6.8 µU/ml, and bioavailability of 6.8 ± 2.0 %. These results indicate
that complexing agent SPC had little permeation enhancing effects in delivering insulin
nasally.
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Significantly higher absorption was observed when insulin solubilized in aqueous
phase of blank NE-8-5X and Ins-SPC complex loaded NE-8-5X formulations were
administered. Blank NE-8-5X with insulin in aqueous phase showed Cmax of 199.7 ± 38.6
µU/ml (p < 0.01) with bioavailability of 43.8 ± 7.1 % (p < 0.01) compared to the free
solution form and complex suspension with Tmax of about 11 min. However, when insulin
was loaded in the oil phase of nanoemulsion system (NE-8-5X), maximum plasma
concentration was observed to be 255.9 ± 35.9 µU/ml (p < 0.001) and bioavailability was
determined to be 68.8 ± 8.7 % (p < 0.001) compared to the free solution form and
complex suspension with Tmax of 15 min.
These results were in correlation with in vitro transport results which indicated that
the enhanced absorption of insulin could be due to permeation enhancing properties of
formulation component capmul MCM. Although capmul MCM at concentrations higher
than 1% showed toxic effects on cells, we hypothesize that it may not be as toxic as it is
on cell monolayer for in vivo delivery because of the membrane thickness and fast
membrane recovery. Kim et. al. performed the histological examination of rat’s nasal
membrane 6 h after an intranasal delivery of microemulsion containing 15% of capmul
MCM and observed negligible toxicity to the nasal epithelium (Cho et al., 2012). Our invivo study formulation contains about 6% of capmul MCM which is much lower than the
reported non-toxic concentration. To further confirm and evaluate the toxicity effect of
our formulation on nasal membrane, histological examination was carried out.
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Fig. 19. Blood glucose reduction in healthy rats following 1 IU/kg subcutaneous dose and
3.6 IU/kg nasal delivery dose (mean ± SEM, n = 3-6).

91

Fig. 20. Plasma insulin conc. vs time profiles following nasal administration of 3.6 IU/kg
and 1 IU/kg subcutaneous administration in healthy rats (mean ± SEM, n = 3-6).
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±
8.7***

c68.8

± 3.6
***

a36.2

±
24.0***

c190.9

b43.8

± 7.1**

30.1 ± 4.1**

±
19.6**

b121.7

169.4 ±
23.3**

11.7 ± 2.1

±
38.6**

b199.7

Insulin in
Aq. Phase of
NE-8 (n=6)

6.8 ± 2.0

23.5 ± 2.9

18.9 ± 5.6

132.6 ±16.5

35.0 ± 10.2

12.9 ± 6.8

Complex
Suspension
(n=3)

5.5 ± 1.4

13.1 ± 2.3

15.5 ± 3.8

73.5 ± 12.8

20.0 ± 5.0

5.8 ± 1.9

Insulin
Solution
(n=3)

-

11.8 ± 1.4

-

66.6 ± 7.7

-

-

Buffer PBS
(n=5)

100

100

77.1 ± 12.6

156.5 ± 11.0

6.8 ± 1.5

77.6 ± 9.2

Insulin
Solution
S.C. (n=6)

*p < 0.05, **p < 0.01, ***p < 0.001, significant difference compared with the insulin solution group. ap < 0.05, bp < 0.01, cp < 0.001,
significant difference compared with the complex suspension group.
Nasal administration dose = 3.6 IU/kg, subcutaneous administration dose = 1IU/kg
Cmax: maximum insulin concentration; Tmax: time to reach Cmax; AAC: area above the glucose-time curve; AUC: area under the insulintime curve; PA: relative pharmacological availability compared with s.c; BA: relative bioavailability compared with s.c.

Relative BA
(%)

Relative PA
(%)

AUC0-240 min
(µU * h/ml)

±
20.2***

a203.6

15.0

Tmax (min)

AAC0-240 min
(% Glu.
Reduction*
h)

±
35.9***

c255.9

NE-8
Formulation
(n=6)

Cmax
(µU/ml)

Group
Name

Table 10. Pharmacokinetic and pharmacodynamic parameters (mean ± SEM, n = 3-6).

Histology Study

Toxicity of the various formulations on the nasal epithelium was evaluated by
histological staining. No apparent damage to the mucosal membrane was observed in
case of insulin complex-loaded nanoemulsion (NE-8-5X) as compared to insulin solution.
The results are presented in Fig. 21.
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A.

B.

Fig. 21. Photomicrographs of nasal mucosal membrane (vertical sections cut through the
respiratory mucosa of nasal cavity) following nasal administration of A.) Insulin solution
in PBS and B.) Ins-SPC complex loaded nanoemulsion (NE-8-5X) C.) Blank
nanoemulsion with insulin in aqueous phase and D.) Ins-SPC complex suspension for 4
h. Tissues were fixed in 10% neutral buffered formalin, decalcified, and stained with H &
E. The microscopic observation was carried out using a 40X objective lens.
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Conclusion
Ins-SPC complex loaded nanoemulsion has promising potential to deliver insulin by
nasal route.
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CHAPTER 6: FUTURE STUDIES

Following studies will be conducted in future:
1. Evaluation of different doses to measure insulin concentration and blood glucose
reduction in healthy and diabetic rats for dose response curve using Ins-SPC
complex loaded nanoemulsion system.
2. Chronic toxicity effect of developed formulation on rat’s nasal mucosa after
multiple dose administration will be investigated by histological examination.
3. Evaluation of nasal absorption of insulin through nanoemulsion system where
insulin is loaded into the oil phase as well as in the aqueous phase.
4. Use of insulin analogues with developed formulation to determine absorption
profile in-vivo.
5. Exploration of developed formulation for treatment of Alzheimer’s disease.
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